Olorofim治疗选择有限侵袭性真菌病的单臂开放标签2b期研究
这项单臂、开放标签2b期研究纳入204例治疗选择有限的确诊侵袭性真菌病或很可能侵袭性肺曲霉病患者,评估口服Olorofim的疗效与安全性。Olorofim在治疗选择有限的患者中显示疗效和良好耐受性。
要点
- Olorofim对多种难治真菌(包括唑类耐药曲霉)显示活性
核心结论
- Olorofim在治疗选择有限或没有治疗选择的侵袭性真菌病患者中显示出疗效和良好耐受性,但需进一步研究明确其作用。
研究设计与样本
- 单臂、开放标签、2b期研究,自11个国家22个中心招募≥16岁确诊IFD或很可能侵袭性肺曲霉病且治疗选择有限或无的患者。
- 前58例接受体重为基础的口服Olorofim负荷剂量180-300 mg分2-3次(第1天),随后120-240 mg/日分2-3次(第2天起)。
- 基于前25例药代动力学数据,自第59例起改为第1天150 mg每日两次负荷,随后固定维持剂量90 mg每日两次至第84天(主要治疗期),必要时延长治疗。
- 主要终点为第42天全局应答率(基于临床、影像学和真菌学应答的复合终点),由数据审查委员会(DRC)判定成功或失败。
- 疗效分析纳入经DRC确认为IFD且至少接受一剂Olorofim的改良意向治疗人群;安全性分析纳入所有至少接受一剂Olorofim的患者。
主要发现
- 2018年6月6日至2022年9月8日共入组204例患者,203例接受治疗,202例(124男,78女)经DRC判定为IFD。
- 病原体包括曲霉属(n=101,含22株唑类耐药株)、Lomentospora prolificans(n=26)、Scedosporium spp(n=22)、Coccidioides spp(n=41)和其他真菌(n=12)。
关键数值与推荐
- 全局应答成功定义为临床、影像学和真菌学三项均完全或部分改善;失败定义为任一项稳定或进展或全因死亡。
- 主要治疗期203例平均给药持续时间73天(SD 25),中位84天(范围2-99,IQR 78-87)。
- 主要治疗期后接受延长治疗的114例平均给药持续时间361天(SD 220),中位309天(范围38-988,IQR 180-502)。
- 医学显著的肝酶升高判定至少可能与Olorofim相关者20/203例(10%),14例(7%)经剂量调整缓解,6例(3%)停药。
- 胃肠道不耐受20例(10%),主要为轻中度且自限;无治疗相关死亡。
临床怎么用
- 对于治疗选择有限或没有治疗选择的侵袭性真菌病患者,Olorofim可作为候选治疗方案。
- 治疗期间需监测肝酶,肝酶升高时可经剂量调整或停药管理。
- 胃肠道不耐受多为轻中度自限,可对症处理。
- 延长治疗可用于需要持续治疗的患者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Only a small number of antifungal therapies for invasive fungal disease (IFD) are currently available, and many pathogens are resistant to one or more of these therapies. Olorofim, the first orotomide antifungal agent to be developed, is active against fungi that are resistant to registered therapies. It impairs fungal pyrimidine biosynthesis, leading to cell death. We sought initial data on the efficacy and safety of olorofim as a therapy for IFD. METHODS: In this single-arm, open-label, phase 2b study, patients aged 16 years or older with few or no treatment options for proven IFD or probable invasive pulmonary aspergillosis were recruited from 22 centres in 11 countries. The first 58 patients received a weight-based loading dose of oral olorofim 180-300 mg in two to three divided doses on day 1 followed by 120-240 mg daily in two to three divided doses from day 2 onwards. On the basis of pharmacokinetic data from the first 25 patients, dosing was simplified from patient 59 onwards to a loading dose of 150 mg twice on day 1 followed by a fixed maintenance dose of 90 mg twice a day up to day 84 (main treatment phase) with extended therapy as needed. The primary endpoint was global response rate (based on a composite of clinical, radiological, and mycological responses) at day 42, determined as success (complete or partial improvement in all three components) or failure (stable disease or progression on any one component or death from any cause) by a data review committee (DRC). Secondary efficacy endpoints included global response rate at day 84 and all-cause mortality at day 42 and day 84. Global response rate with stable disease classified as success and response rate in the clinical component of the global response at day 42 and day 84 were also assessed. Efficacy was analysed for all patients who were confirmed by the DRC to have an IFD and who received at least one dose of olorofim (the modified intention-to-treat population). Safety was analysed in all patients who received at least one dose of olorofim (the safety population). This trial is registered with ClinicalTrials.gov, NCT03583164, and is completed. FINDINGS: Between June 6, 2018, and Sept 8, 2022, 204 patients were enrolled. Of these, 203 were treated with olorofim and 202 (124 male, 78 female) had DRC-adjudicated IFD. Causative pathogens were Aspergillus spp (n=101, including 22 azole-resistant strains), Lomentospora prolificans (n=26), Scedosporium spp (n=22), Coccidioides spp (n=41), and other fungi (n=12). Successful global response was confirmed in 58 of 202 patients (28·7%, 95% CI 22·6-35·5) at day 42 and in 55 patients (27·2%, 21·2-33·9) at day 84. Successful global response with stable disease included in the definition of success was seen in 152 patients (75·2%, 68·7-81·0) at day 42 and in 128 patients (63·4%, 56·3-70·0) at day 84. A successful clinical response was seen in 121 patients (59·9%, 52·8-66·7) at day 42 and in 109 patients (54·0%, 46·8-61·0) at day 84. All-cause mortality was documented in 24 patients (11·9%, 7·8-17·2) at day 42 and in 33 patients (16·3%, 11·5-22·2) at day 84. Mean dosing duration was 73 days (SD 25) for the 203 patients in the main treatment phase (median 84 days [range 2-99, IQR 78-87]) and 361 days (SD 220) for the 114 patients who received extended treatment after the main phase (median 309 days [38-988, 180-502]). Medically significant liver enzyme elevations adjudicated to be at least possibly due to olorofim occurred in 20 (10%) of 203 patients and were managed to resolution by dose modification in 14 (7%) patients or by discontinuation of treatment in six (3%). Gastrointestinal intolerance, which occurred in 20 (10%) patients, was predominantly reported as mild or moderate and self-limiting. There were no treatment-related deaths. INTERPRETATION: Olorofim showed efficacy and good tolerability in patients with IFD with few or no treatment options. Further studies will be needed to fully delineate the role of this new antifungal agent. FUNDING: F2G.
引用
- Maertens JA, Thompson GR, Spec A, et al. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. Lancet Infect Dis. 2025. PMID: 40541222. doi:10.1016/S1473-3099(25)00224-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。